Efficacy of 5HT in migraine.
Buzzi
M G
MG
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002415:Cats; D003392:Cranial Sinuses; D004558:Electric Stimulation; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D010080:Oxazoles / Q000494:pharmacology; D023303:Oxazolidinones; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000502:physiology* / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D018170:Sumatriptan / Q000494:pharmacology; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use*
C470302:HTR1B protein, human; D010080:Oxazoles; D023303:Oxazolidinones; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C089750:zolmitriptan; D012701:Serotonin; D018170:Sumatriptan